

ONE TUMOUR, MANY FACES: OPTIMISING TESTING, TARGETING AND MONITORING ONCOGENE-ADDICTED NSCLC BEYOND EGFR

Chairs

Marina Garassino, Chicago, IL, USA

Fernando Lopez-Rios, Madrid, Spain

THURSDAY, 31 MARCH 2022

11:45 – 13:15 CEST, CONGRESS HALL

11:45	Introduction	Marina Garassino, Chicago, IL, USA
11:55	Tissue testing for actionable biomarkers in patients with advanced NSCLC: Scientific and implementation perspectives and the positioning of molecular tumour boards	Fernando Lopez-Rios, Madrid, Spain
12:15	An overview of molecular epidemiology of rare molecular aberrations and matching treatment strategies for patients with non-EGFR, oncogene-addicted advanced NSCLC	Fabrice Barlesi, Paris, France
12:35	RET-fused NSCLC: State of the art treatment of advanced disease, including sanctuary sites	Marina Garassino, Chicago, IL, USA
12:55	Q&A and live discussion	All speakers
13:10	Concluding remarks	Fernando Lopez-Rios, Madrid, Spain

This educational activity is provided by
ESMO and supported by Eli Lilly.

Lilly

